Propel Bio Management, LLC
In its 13F for Q2 2024 (holdings as of June 30, 2024, filed August 12, 2024), Propel Bio Management, LLC reported 24 stock positions worth $154.2 million. Its top holding was Applied Therapeutics (APLT) at 19.9% of the portfolio, followed by Plains GP (PAGP, 16.8%) and Tscan Therapeutics (TCRX, 7.9%). Compared with Q1 2024, it opened 4 new positions, sold out of 8 and added to 4. The biggest buy was a new position in Plains GP (PAGP) and the biggest sale an exit from Simplify Enhanced Income ETF (HIGH).
- Most Recent 13F
- Q2 2026
- Location
- Los Angeles, CA
- CIK
- 0001969764
- Portfolio Value
- $154.2M (Q2 2024)
- SEC Filing
- 0001829126-24-005385 ↗ filed Aug 12, 2024
Holdings Value
Holdings 24 stocks · $154.2M
| APLT Applied Therapeutics Inc. | 19.89% | 6,567,858 | $30.7M | Add +7.5% |
| PAGP Plains GP Holdings LP | 16.75% | 1,372,360 | $25.8M | New |
| TCRX Tscan Therapeutics Inc. | 7.92% | 2,087,139 | $12.2M | No change |
| MDGL Madrigal Pharmaceuticals Inc. | 7.82% | 43,032 | $12.1M | No change |
| ACHV Achieve Life Sciences Inc. | 7.48% | 2,453,092 | $11.5M | No change |
| PHAT Phathom Pharmaceuticals Inc. | 5.81% | 869,927 | $9.0M | No change |
| AKRO Akero Therapeutics Inc. | 4.99% | 327,752 | $7.7M | No change |
| RNAM Avidity Biosciences Inc. | 4.73% | 178,500 | $7.3M | No change |
| ARDX Ardelyx Inc. | 4.44% | 924,583 | $6.9M | Add +55.6% |
| ABEO Abeona Therapeutics Inc. | 3.43% | 1,248,044 | $5.3M | New |
| FULC Fulcrum Therapeutics Inc. | 3.02% | 750,000 | $4.7M | No change |
| ATHIRA PHARMA INC | 2.57% | 1,492,792 | $4.0M | No change |
| TSAT Telesat Corp. | 2.16% | 365,781 | $3.3M | Add +25.8% |
| VRCA Verrica Pharmaceuticals Inc. | 2.01% | 424,937 | $3.1M | New |
| KURA Kura Oncology Inc. | 1.74% | 130,000 | $2.7M | No change |
| EIGRQ Eiger Biopharmaceuticals Inc. | 1.20% | 146,381 | $1.9M | No change |
| SNDX Syndax Pharmaceuticals Inc. | 1.11% | 83,259 | $1.7M | No change |
| KYMR Kymera Therapeutics Inc. | 1.09% | 56,359 | $1.7M | No change |
| KYN Kayne Anderson Energy Infra | 0.98% | 147,033 | $1.5M | No change |
| TRVI Trevi Therapeutics Inc. | 0.50% | 260,000 | $775K | No change |
| FIDELITY INV MMTRSY 1 680 | 0.21% | 317,014 | $317K | Add +49.9% |
| CYBIN INC | 0.15% | 850,000 | $230K | No change |
| MAAT PHARMA SACA | 0.01% | 1,362 | $10K | New |
| CHINOOK THERAPEUTICS CVR | 0.01% | 79,357 | $10K | No change |
Portfolio Sells Q1 2024 → Q2 2024
| HIGH Simplify Enhanced Income ETF | Sold out | 0.00% | −16.29 |
| DAWN Day One Biopharmaceuticals I | Sold out | 0.00% | −2.60 |
| MBB iShares MBS ETF | Sold out | 0.00% | −1.21 |
| MIRM Mirum Pharmaceuticals Inc. | Sold out | 0.00% | −1.02 |
| MRNS Marinus Pharmaceuticals Inc. | Sold out | 0.00% | −0.95 |
| STRO Sutro Biopharma Inc. Com SHS | Sold out | 0.00% | −0.64 |
| XFOR X4 Pharmaceuticals Inc. | Sold out | 0.00% | −0.43 |
| LQD Ishr Ibx Usd Invgd CB ETF-Ui | Sold out | 0.00% | −0.28 |
Portfolio Buys Q1 2024 → Q2 2024
| PAGP Plains GP Holdings LP | New | 16.75% | +16.75 |
| ABEO Abeona Therapeutics Inc. | New | 3.43% | +3.43 |
| VRCA Verrica Pharmaceuticals Inc. | New | 2.01% | +2.01 |
| ARDX Ardelyx Inc. | Add +55.6% | 4.44% | +1.92 |
| TSAT Telesat Corp. | Add +25.8% | 2.16% | +0.70 |
| FIDELITY INV MMTRSY 1 680 | Add +49.9% | 0.21% | +0.08 |
| MAAT PHARMA SACA | New | 0.01% | +0.01 |
| APLT Applied Therapeutics Inc. | Add +7.5% | 19.89% | −4.30 |
All Filings
| Quarter | Positions | 13F Reported Value | Top Holdings |
|---|---|---|---|
| Q2 2026 | 29 | $191.1M | PAGP, ACHV, CORT, PHAT, DCTH |
| Q1 2026 | 38 | $158.7M | PAGP, ACHV, PHAT, DCTH, CORT |
| Q4 2025 | 20 | $117.1M | PAGP, ACHV, PHAT, VRDN, MIST |
| Q3 2025 | 16 | $99.9M | PAGP, ACHV, AKRO, MIST, APLT |
| Q2 2025 | 16 | $82.4M | PAGP, ACHV, AKRO, PHAT, ABEO |
| Q1 2025 | 18 | $86.1M | PAGP, MDGL, AKRO, PHAT, ACHV |
| Q4 2024 | 21 | $100.7M | PAGP, MDGL, AKRO, ACHV, APLT |
| Q3 2024 | 21 | $172.4M | APLT, PAGP, PHAT, ACHV, TCRX |
| Q2 2024 | 24 | $154.2M | APLT, PAGP, TCRX, MDGL, ACHV |
| Q1 2024 | 28 | $171.8M | APLT, HIGH, TCRX, MDGL, ACHV |